Targeting KRAS in Cancer Therapy: Beyond Inhibitors

Chunhui Chen; Zhiqiang Peng; Lingqiang Zhang

doi:10.1002/mco2.70267

MedComm ›› 2025, Vol. 6 ›› Issue (7) : e70267 DOI: 10.1002/mco2.70267

HIGHLIGHT

Targeting KRAS in Cancer Therapy: Beyond Inhibitors

Author information +

History +

PDF

Cite this article

Download citation ▾

Chunhui Chen, Zhiqiang Peng, Lingqiang Zhang. Targeting KRAS in Cancer Therapy: Beyond Inhibitors. MedComm, 2025, 6(7): e70267 DOI:10.1002/mco2.70267

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	J. Popow, W. Farnaby, A. Gollner, et al., “Targeting Cancer with Small-molecule Pan-KRAS Degraders,” Science 385, no. 6715 (2024): 1338-1347.

[2]	Y. Chang, Q. Chen, H. Li, et al., “The UBE2F-CRL5(ASB11)-DIRAS2 Axis Is an Oncogene and Tumor Suppressor Cascade in Pancreatic Cancer Cells,” Developmental Cell 59, no. 10 (2024): 1317-1332.e5.

[3]	Q. Chen, X. Xiong, and Y. Sun, “USP10 deubiquitylates and Stabilizes DIRAS2 to Suppress the Growth of Pancreatic Cancer Cells,” MedComm 5, no. 10 (2024): e751.

[4]	A. Singhal, B. T. Li, and E. M. O'Reilly, “Targeting KRAS in Cancer,” Nature Medicine 30, no. 4 (2024): 969-983.

[5]	M. Ghazi Vakili, C. Gorgulla, J. Snider, et al., “Quantum-computing-enhanced Algorithm Unveils Potential KRAS Inhibitors,” Nature Biotechnology Published online January 22, 2025.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.